López García A, Paz Martínez D, Orea Solano M, Hernández Valencia G, Ramírez García A, Ramírez Ojeda H, Sánchez Medal L F, Soda Mehry A, Velarde Domínguez T, Betancourt Suárez M A, Méndez Vera J L
Servicio de alergología e inmunología clínica, Hospital Universitario de Puebla.
Rev Alerg Mex. 2001 Nov-Dec;48(6):168-72.
Allergic rhinitis affects 20 million of people in United States and a higher figure all around the world.
To evaluate the efficacy and safety of fexofenadine compared with certirizine in the treatment of allergic rhinitis.
It was carried out a prospective, double blind, comparative, randomized and multicentric study in patients with allergic rhinitis, with ages between 12 and 65 years. In the first phase, placebo was administered during three days to all the patients; and then, they were randomly allocated to receive fexofenadine 120 mg or cetirizine 10 mg in one dose a day during 14 days. Laboratory and cabinet tests at the beginning and at the end were performed to value security, as well as a global evaluation of the researcher to estimate effectiveness.
176 patients were included, 63.6% were women, average age was 27 years (+/- 12), 47.7% received fexofenadine and 52.2%, cetirizine. There was not significant difference in parameters of effectiveness nor of security in the studied group.
The results of the present study confirm the efficacy and safety of the antihistaminic fexofenadine in the treatment of allergic rhinitis.
在美国，过敏性鼻炎影响着2000万人，全球受影响人数更多。
评估非索非那定与西替利嗪相比治疗过敏性鼻炎的疗效和安全性。
对年龄在12至65岁之间的过敏性鼻炎患者进行了一项前瞻性、双盲、对比、随机和多中心研究。在第一阶段，所有患者服用三天安慰剂；然后，他们被随机分配接受非索非那定120毫克或西替利嗪10毫克，每天一次，共14天。在开始和结束时进行实验室和体格检查以评估安全性，以及由研究人员进行整体评估以估计疗效。
纳入176名患者，63.6%为女性，平均年龄27岁（±12），47.7%接受非索非那定治疗，52.2%接受西替利嗪治疗。研究组在疗效和安全性参数方面无显著差异。
本研究结果证实了抗组胺药非索非那定治疗过敏性鼻炎的疗效和安全性。
Zotero 插件